Unique challenges faced by the clinical evaluation of dengue vaccines.
about
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodiesRecombinant Dengue Virus 4 Envelope Glycoprotein Virus-Like Particles Derived from Pichia pastoris are Capable of Eliciting Homotypic Domain III-Directed Neutralizing Antibodies.Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies.Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated VaccineChallenges for the formulation of a universal vaccine against dengue.Challenges in reducing dengue burden; diagnostics, control measures and vaccines.Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies.Development of a capillary zone electrophoresis method for dose determination in a tetravalent dengue vaccine candidate.Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo.
P2860
Q26314715-75CC97BB-945D-4578-88AA-64D0D38D03D5Q30395028-D1A3F296-DF98-447D-A06C-D23A0B0E4853Q34746139-38985D93-1D34-488D-80D9-E98AA77A94C8Q35976650-78F9EBC9-8163-4079-B342-490BC572D5A0Q38121757-85C54498-2187-4221-9437-7D2C49530C3BQ38140035-362DF88E-0004-4B3B-9708-5B5DE6BD2DBAQ40136145-B9127AF3-EBE7-4E46-9064-77909FD8D35BQ40140795-1FF79ED4-DA47-4051-9CAB-1F677011D841Q47549097-835C1FA1-DE16-4283-8270-C4B292ECB640
P2860
Unique challenges faced by the clinical evaluation of dengue vaccines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Unique challenges faced by the clinical evaluation of dengue vaccines.
@en
Unique challenges faced by the clinical evaluation of dengue vaccines.
@nl
type
label
Unique challenges faced by the clinical evaluation of dengue vaccines.
@en
Unique challenges faced by the clinical evaluation of dengue vaccines.
@nl
prefLabel
Unique challenges faced by the clinical evaluation of dengue vaccines.
@en
Unique challenges faced by the clinical evaluation of dengue vaccines.
@nl
P2860
P356
P1476
Unique challenges faced by the clinical evaluation of dengue vaccines.
@en
P2093
Robert Edelman
P2860
P304
P356
10.1586/ERV.10.159
P577
2011-02-01T00:00:00Z